<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02527733</url>
  </required_header>
  <id_info>
    <org_study_id>2129</org_study_id>
    <nct_id>NCT02527733</nct_id>
  </id_info>
  <brief_title>Retinal Sensitivity in BRVO After Anti-VEGF Therapy</brief_title>
  <official_title>Retinal Sensitivity in Branch Retinal Vein Occlusion After Anti-VEGF Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fukushima Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fukushima Medical University</source>
  <brief_summary>
    <textblock>
      The efficacy of anti-vascular endothelial growth factor (VEGF) therapy for branch retinal
      vein occlusion (BRVO) is shown, but its effect on retinal sensitivity is not fully
      investigated. The purpose of this study is to compare the changes in retinal sensitivity
      after ranibizumab therapy or combination therapy of ranibizumab and laser photocoagulation in
      eyes with BRVO.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2015</start_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retinal sensitivity measured by microperimetry (MP-3, NIDEK, Japan)</measure>
    <time_frame>At 12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Branch Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>Ranibizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After initial single intravitreal injection of ranibizumab (0.5mg), participants receive monthly as-needed injection of ranibizumab (0.5mg) when visual acuity is less than 1.0 and foveal thickness is more than 250 micrometers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranibizumab and laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After initial single intravitreal injection of ranibizumab (0.5mg), participants receive monthly as-needed injection of ranibizumab (0.5mg) when visual acuity is less than 1.0 and foveal thickness is more than 250 micrometers. Macular laser photocoagulation will be performed when visual acuity is less than 1.0 and foveal thickness is more than 250 micrometers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <arm_group_label>Ranibizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab and laser</intervention_name>
    <arm_group_label>Ranibizumab and laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment naive patients of branch retinal vein occlusion with visual acuity of less
             than 1.0 and macular edema of more than 250 micrometers in foveal thickness.

        Exclusion Criteria:

          -  Patients with history of treatment for branch retinal vein occlusion, possibility of
             pregnancy, allergy for ranibizumab, intraocular infection, or severe inflammation will
             be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Akira Ojima, M.D., Ph.D</last_name>
    <phone>+81-24-548-2111</phone>
    <email>ao@fmu.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Ophthalmology, Fukushima Medical University</name>
      <address>
        <city>Fukushima</city>
        <zip>9601295</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akira Ojima, M.D., Ph.D</last_name>
      <phone>+81-24-548-2111</phone>
      <email>ao@fmu.ac.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2015</study_first_submitted>
  <study_first_submitted_qc>August 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2015</study_first_posted>
  <last_update_submitted>August 17, 2015</last_update_submitted>
  <last_update_submitted_qc>August 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fukushima Medical University</investigator_affiliation>
    <investigator_full_name>Akira Ojima</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

